Growing Personalized Medicine Capabilities, PGXL Inks Partnership with AutoGenomics
April 06, 2011
Growing Personalized Medicine Capabilities, PGXL Inks Partnership with AutoGenomics
PGXL will use AutoGenomics' Infiniti analyzer for various personalized medicine applications. Specifically, PGXL plans to use AutoGenomics' FDA-cleared Infiniti warfarin assay and CYP450 2C19 assay.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter - Trovagene, MD Anderson Partner on Transrenal BRAF Mutation Detection
January 3, 2013 / PCR Insider - Study Finds KRAS Testing in Metastatic CRC Saves Money, but Questions Value of EGFR Inhibitors
November 28, 2012 / Pharmacogenomics Reporter - Qiagen Enters Companion Dx Market with Approval of KRAS Test Kit for Erbitux; LDT Impact Unknown
July 11, 2012 / Pharmacogenomics Reporter - Life Tech Expands CastPCR Mutation Detection Assays to Include 21 Additional Cancer Genes
April 5, 2012 / PCR Insider